Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: Olanzapine: Olanzapine is an atypical antipsychotic approved for use in Schizophrenia. It will be given at the approved of 5-20mg/day for 10weeks.
Control Intervention1: Risperidone: Ri
Sponsors
Government Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis of schizophrenia according to ICD-11 Drug naïve or not on any antipsychotic drug from past 4 weeks
Exclusion criteria
Exclusion criteria: Patients with co-morbid substance dependence (except nicotine and caffeine) Patients who are lactating or pregnant. Patients with any unstable medical (hypothyroidism, diabetes insipidus, kidney disease, liver disease, chronic heart disease) neurological or surgical disorders. Patients with history of active infection in last 2 weeks. Patients with history of autoimmune diseases. Patients on any immunosuppressant drug. Acutely suicidal patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess and compare the levels of interleukins and TNF-alpha in patients of schizophrenia on olanzapine and risperidone.Timepoint: 0week, 2weeks, 10weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess and compare the early response in relation to changes in interleukins and TNF-alpha levels.Timepoint: 0 week, 2weeks, 10 weeks;To assess and compare the clinical response, Quality of Life (QoL) and sexual wellbeing with olanzapine and risperidone.Timepoint: 0week, 10weeks | — |
Countries
India
Contacts
Public ContactDr Karan Singh Nagarkoti
Government Medical College and Hospital, Sector 32, Chandigarh
Outcome results
None listed